Kris on Oncology
![Mark G. Kris, MD](https://cdn.statically.io/img/img.medscape.com/person/kris_mark_2018.jpg)
+ Add to Email Alerts
- Rethinking Clinical Trial Design and Cure in NSCLC
- Call to Action: Prioritizing Cure in Lung Cancer
- 'We Need to Rethink Our Options': Lung Cancer Recurrence
- Neoadjuvant Bests Adjuvant Therapy in Lung Cancer
- Avoid Counseling Fatigue: 'Don't Give Up'
- Success in Clinical Trials: Putting Patients First
- Listen to Your Patients: Improving Antiemetic Regimens
- Toward a Cure: Chemotherapy Plus TKI in EGFR-Mutant NSCLC
- Community: Key to Keeping Up-to-Date in Thoracic Oncology
- Disappointing Sotorasib Results: How to Move Forward
- Open Medical Institute: Physicians Improving Patient Care
- Include Neoadjuvant Chemotherapy in Stage II-III Lung Cancer
- ASCO Insights: Impacts on Lung Cancer Care
- Unlikely Breakthrough of the Year: Chemo for Lung Cancer
- We're in a 'Brave New World' of Low-Grade Toxicities
- NSCLC: Case for Combining Chemo and Osimertinib
- How to Think About Second-Line Therapy in NSCLC
- Neoadjuvant Advantages: Treating Locally Advanced Lung Cancer
- Add Chemo for Fit Patients With EGFR-Mutant Lung Cancer
- New 'C Word': Cure Should Be Goal for Lung Cancer Patients